首页|Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis

Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Temozolomide(TMZ)represents a standard-of-care chemotherapeutic agent in glioblastoma(GBM).However,the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma.Although specific innovative approaches,such as immunotherapy,have shown favorable clinical outcomes,the inherent invasiveness of most gliomas continues to make them challenging to treat.Consequently,there is an urgent need to identify effective therapeutic targets for gliomas to overcome chemoresistance and facilitate drug development.This investigation used mass spectrometry to examine the proteomic profiles of six pairs of GBM patients who underwent standard-of-care treatment and surgery for both primary and recurrent tumors.A total of 648 proteins exhibiting significant differential expression were identified.Gene Set Enrichment Analysis(GSEA)unveiled notable alterations in pathways related to METABOLISM_OF_LIPIDS and BIOLOGICAL_OXIDATIONS between the primary and recurrent groups.Validation through glioma tissue arrays and the Xiangya cohort confirmed substantial upregulation of inositol 1,4,5-triphosphate(IP3)kinase B(ITPKB)in the recurrence group,correlating with poor survival in glioma patients.In TMZ-resistant cells,the depletion of ITPKB led to an increase in reactive oxygen species(ROS)related to NADPH oxidase(NOX)activity and restored cell sensitivity to TMZ.Mechanistically,the decreased phosphorylation of the E3 ligase Trim25 at the S100 position in recurrent GBM samples accounted for the weakened ITPKB ubiquitination.This,in turn,elevated ITPKB stability and impaired ROS production.Furthermore,ITPKB depletion or the ITPKB inhibitor GNF362 effectively overcome TMZ chemoresistance in a glioma xenograft mouse model.These findings reveal a novel mechanism underlying TMZ resistance and propose ITPKB as a promising therapeutic target for TMZ-resistant GBM.

Yuanliang Yan、Shangjun Zhou、Xi Chen、Qiaoli Yi、Songshan Feng、Zijin Zhao、Yuanhong Liu、Qiuju Liang、Zhijie Xu、Zhi Li、Lunquan Sun

展开 >

Department of Pharmacy,Xiangya Hospital,Central South University,Changsha 410008,China

Department of Neurosurgery,Xiangya Hospital,Central South University,Changsha 410008,China

Department of Pathology,Xiangya Hospital,Central South University,Changsha 410008,China

Xiangya Cancer Center,Xiangya Hospital,Central South University,Changsha 410008,China

Key Laboratory of Molecular Radiation Oncology Hunan Province,Changsha 410008,China

Institute of Cancer Research,National Clinical Research Center for Geriatric Disorders(Xiangya),Xiangya Hospital,Central South University,Changsha 410008,China

展开 >

国家自然科学基金国家自然科学基金Science and Technology Innovation Program of Hunan ProvinceScience and Technology Innovation Program of Hunan Province湖南省自然科学基金项目湖南省自然科学基金项目

82272659820300872022RC12102021RC30292022JJ300732021JC0002

2024

10.1038/s41392-024-01763-x

信号转导与靶向治疗(英文)

信号转导与靶向治疗(英文)

CSTPCD
ISSN：
年,卷(期)：2024.9(4)
  • 53